Last updated: February 23, 2026
What is the Drug Associated with NDC 60505-0257?
NDC 60505-0257 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody used to treat multiple sclerosis (MS), including relapsing forms and primary progressive MS. Approved by the FDA in March 2017, Ocrevus is marketed by Genentech, a Roche subsidiary.
Market Overview
Market Size and Growth
- The multiple sclerosis treatment market was valued at approximately $24 billion in 2022.
- Projected CAGR (2023–2028): 4.5% (MarketWatch, 2023).
- Ocrevus's share: Estimated at 20–25% within the MS therapeutic segment in the U.S., with expanding presence in Europe and Asia.
Key Competitors
| Drug |
Indication |
Year Approved |
Market Share (2022) |
Price (USD/month) |
| Ocrevus (ocrelizumab) |
Relapsing MS, PAMS |
2017 |
20–25% |
$7,500 |
| Tecfidera (dimethyl fumarate) |
Relapsing MS |
2013 |
15–20% |
$7,000 |
| Tysabri (natalizumab) |
Relapsing MS, PAMS |
2004 |
10–15% |
$8,500 |
| Aubagio (teriflunomide) |
Relapsing MS |
2012 |
5–10% |
$5,100 |
Clinical and Commercial Expansion
- Approved for primary progressive MS (2019), broadening potential market.
- Sales driven by increased adoption in PAMS and PPMs.
- Growing use in Europe after EMA approval in 2018.
Market Drivers
- Increasing diagnosis rates globally.
- Prescribing shifts favoring high-efficacy DMTs.
- Patient preference for less frequent dosing (Ocrevus is administered biannually).
Pricing Strategy and Reimbursement
- List price in U.S.: $7,500 per 300 mg infusion.
- Reimbursement rate: Varies by insurer but generally covered under pharmacy benefits.
- Discounting practices: Manufacturers offer rebates and patient assistance programs.
Cost Comparison
| Drug |
Monthly Price (USD) |
Dosing Frequency |
Indications |
| Ocrevus |
$7,500 |
Two infusions annually |
Relapsing MS, PAMS, PPM |
| Tecfidera |
$7,000 |
Daily oral |
Relapsing MS |
| Tysabri |
$8,500 |
Monthly infusions |
Relapsing MS |
Price Projections (2023–2028)
Assumptions
- U.S. list prices remain stable, with minor adjustments for inflation.
- Volume growth driven by increased diagnosis and expanding indications.
- Potential price erosion due to biosimilar entries not anticipated before 2028.
Forecast Summary
| Year |
Estimated Revenue (USD Billions) |
Key Factors |
| 2023 |
2.2 |
Stabilized market share, moderate volume growth |
| 2024 |
2.4 |
Slight price increases, bigger patient base |
| 2025 |
2.6 |
Market saturation with existing indications |
| 2026 |
2.8 |
Introduction of biosimilars possible post-2028 |
| 2027 |
3.0 |
Patent exclusivity continues, stable pricing |
Future Considerations
- Biosimilar competition expected post-2028, potentially reducing price.
- Emerging oral and IV therapies may alter market dynamics.
- Approval expansion to other neurodegenerative conditions could increase the addressable market.
Key Takeaways
- Ocrevus is a high-efficacy MS therapy with stable pricing, generating over $2 billion in annual revenue.
- Market growth will result from increased diagnosis and broader indication approvals.
- Price stability is expected until biosimilar entry, which could significantly impact pricing and market share.
- Market share dominance depends on adoption in Europe and Asia, driven by regulatory approvals.
- Competitive landscape shifts with orally administered and biosimilar therapies post-2028 may alter long-term projections.
Frequently Asked Questions
1. What factors could influence Ocrevus’s future pricing?
Market competition, biosimilar entry, regulatory changes, and reimbursement negotiations.
2. How does Ocrevus’s pricing compare globally?
Pricing varies by country due to pricing regulations; U.S. prices are among the highest.
3. What is the potential for biosimilars?
Biosimilars are expected after patent expiration, possibly by 2028, potentially leading to price reductions of 20–40%.
4. Are there any upcoming indications that could expand Ocrevus’s market?
Research into other neurodegenerative diseases is ongoing but unconfirmed.
5. How does Ocrevus’s efficacy impact its market position?
High efficacy in reducing relapses and brain lesions sustains its market share despite high costs.
References
- MarketWatch. (2023). Multiple Sclerosis Treatment Market Size, Share & Trends.
- FDA. (2017). Ocrevus (ocrelizumab) Approval Letter.
- European Medicines Agency. (2018). Ocrevus Summary of Product Characteristics.
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- GlobalData. (2023). MS Drug Market Forecasts.
